Related Experiment Video
Updated: Mar 28, 2026
05:53
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
10.8K
Meta-analysis of the TNF-α-308G/A polymorphism and vitiligo risk
1Department of Dermatology, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Huangshi, China.
Genetics and Molecular Research : GMR
|December 19, 2015
Summary
This meta-analysis found no significant association between the tumor necrosis factor-α (TNF-α)-308G/A polymorphism and vitiligo risk. Further large-scale studies are needed to confirm these findings due to limited current evidence.
Area of Science:
- Genetics
- Immunology
- Dermatology
Background:
- Vitiligo is a chronic autoimmune skin condition with complex genetic factors.
- The tumor necrosis factor-α (TNF-α)-308G/A polymorphism has been investigated as a potential risk factor for vitiligo.
- Previous studies on this association have yielded inconsistent results.
Purpose of the Study:
- To comprehensively evaluate the association between the TNF-α-308G/A polymorphism and vitiligo risk.
- To synthesize existing evidence through a meta-analysis.
Main Methods:
- A systematic literature search was conducted in PubMed and EmBase databases.
- Six case-control studies involving 1391 vitiligo cases and 2455 controls were included.
- Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to assess the association.
Main Results:
- No significant differences in TNF-α-308G/A genotype distribution were observed between vitiligo patients and controls across various genetic models.
- Calculated ORs and CIs indicated a lack of statistically significant association (e.g., OR = 0.65, 95% CI = 0.35-1.23).
- P-values for all comparisons were above the significance threshold (P > 0.05).
Conclusions:
- The TNF-α-308G/A polymorphism does not appear to be significantly associated with vitiligo risk.
- The current evidence is limited, necessitating larger, well-designed studies for confirmation.
- Further research is required to fully elucidate the genetic underpinnings of vitiligo.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
68
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
109
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109
01:29Pharmacogenomics: Identification of New Drug Targets
76
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76
01:27Principles of Pharmacogenetics: Types of Genetic Variants
94
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
94
01:11Genome-wide Association Studies-GWAS
16.6K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
16.6K
01:05Single Nucleotide Polymorphisms-SNPs
19.8K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
19.8K